loader image
Wednesday, August 6, 2025
85.1 F
McAllen
We Welcome your Press Release
- Advertisement -

Cancer patients urged to seek third dose of mRNA COVID-19 vaccine

Translate to Spanish or other 102 languages!

Mayo Clinic Cancer Center announced on Tuesday, Aug. 31, that it is following recommendations from the National Comprehensive Cancer Network that encourage cancer patients to receive a third dose of a messenger RNA COVID-19 vaccine. Image for illustration purposes.

Mega Doctor News

- Advertisement -

by Mayo Clinic 

Newswise — ROCHESTER, Minn. ― Mayo Clinic Cancer Center announced on Tuesday, Aug. 31, that it is following recommendations from the National Comprehensive Cancer Network that encourage cancer patients to receive a third dose of a messenger RNA COVID-19 vaccine. The Moderna and Pfizer COVID-19 vaccines are messenger RNA vaccines.

If patients were vaccinated with the Johnson & Johnson COVID-19 vaccine, no third dose is recommended at this time. The Johnson & Johnson COVID-19 vaccine is an adenovirus vaccine ― not a messenger RNA vaccine.

- Advertisement -

“The updated guidelines for cancer patients from NCCN are based on the latest data and approvals from the FDA (Food and Drug Administration) and CDC (Centers for Disease Control and Prevention) regarding administration of a third messenger RNA vaccine dose for cancer patients and immunocompromised people,” says Robert McWilliams M.D., a medical oncologist. Dr. McWilliams is chair of Mayo Clinic’s Cancer Center Practice Committee.

Here’s who should receive a third dose of a messenger RNA COVID-19 vaccine:

  • Patients with new or recurring solid tumors receiving treatment within one year of their initial vaccine dose, regardless of their type of cancer therapy.
  • Patients with active blood cancers, regardless of whether they receive cancer therapy.
  • Patients who received a stem cell transplant or engineered cellular therapy, such as chimeric antigen receptor-T cell therapy, especially within the past two years.
  • Patients who received allogeneic stem cell transplants and are on immunosuppressive therapy or transplant patients with a history of graft-versus-host disease, regardless of transplant timing.
  • Patients with an additional immunosuppressive condition, such as HIV or patients being treated with immunosuppressive agents unrelated to their cancer therapy.

Review the updated vaccination guidelines for cancer patients on the National Comprehensive Cancer Network website.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

CDC Launches New Campaign to Address Youth Substance Use and Mental Health

Mega Doctor News The back-to-school season is a great time to engage...

DHR Health’s Back-to-School Safety Tips

Mega Doctor News EDINBURG, Texas - As a new school year begins, the...

DHR Health Welcomes Dr. Prateek Suresh Harne, Gastroenterologist

Mega Doctor News EDINBURG, Texas - DHR Health, one of the largest...

STHS Behavioral’s “Raising Resilient Children” Parenting Conference, August 21st

Mega Doctor News There’s no negating that parenting can be challenging and demanding. Despite...
- Advertisement -
×